Fact CheckerSign in

NCT06935149CompletedPhase 1

Detecting Colorectal Cancer With Liver Metastatic Lesions Using Novel Precise Imaging Tools

Detecting Liver Metastatic Lesions in Patients of Colorectal Cancer With Novel Precise Imaging Tools

Source: ClinicalTrials.gov · Last updated 6 Jul 2026

Brief summary (registry, in English)

This study will demonstrate the diagnostic utility of PSMA PET among patients with CRC with liver metastasis.

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
5 (actual)
First submitted
11 Apr 2025
Start date
31 Oct 2025
Primary completion date
30 Apr 2026
Lead sponsor
Primo Biotechnology Co., Ltd
NCT number
NCT06935149

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 5
  • From 31 Oct 2025 to the primary completion date, 30 Apr 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Main inclusion criteria:
  • The participants can voluntarily sign informed consent forms
  • The participants are male/female over 20 years old.
  • The participant is currently undergoing cancer staging based on the previous pathological diagnosis of colorectal cancer
  • The participants are confirmed liver metastasis by CT, abdominal ultrasound, MRI, and FDG PET/CT within 30 days before receiving PSMA-PET/CT.
  • WHO performance status ≦ 2 points
  • The participants can lie on table for two hours during PSMA-PET/CT scanning.
    • Main exclusion criteria: To improve the accurate interpretation of PMSA-PET imaging and reduce the occurrence of related-drug adverse events, the participants will be excluded by following below criteria.
  • The colorectal cancer participants was diagnosed other organs metastases with multiple organ metastases not only the liver.
  • The colorectal cancer participants have undergone any treate after diagnosis of liver metastasis.
  • The participants have suffered from liver dysfunction such as AST/ALT ratio \>2、total bilirubin \>1.5 mg/dL within 6 months.
  • The participants suffered stage IV chronic kidney disease (eGFR\<30 mL/min/1.73 m2) within 6 months.
  • The participants suffered acute kidney injury within 6 months.
  • The participants suffered trauma or fracture.
  • The participants are allergic to any radiopharmaceutical or imaging agent.
  • The participants are history of claustrophobia or are inability to remain quiet during the examination.

Age in the registry: 20 years to 100 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Kaohsiung Chang Gung Memorial Hospital
Coordinator of this site? Confirm its status
Kaohsiung CityTaiwanUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.